1921
Volume 79, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

We describe a case of post-kala-azar dermal leishmaniasis occurring after diagnosis of visceral leishmaniasis in an HIV-1–infected woman. The skin lesions did not recover after treatment with oral miltefosine at 100 mg/day for five cycles of 28 days but responded to treatment with liposomal amphotericin B.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2008.79.715
2008-11-01
2018-12-14
Loading full text...

Full text loading...

/deliver/fulltext/14761645/79/5/0790715.html?itemId=/content/journals/10.4269/ajtmh.2008.79.715&mimeType=html&fmt=ahah

References

  1. Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El Hassan AM, 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3 : 87–98. [Google Scholar]
  2. Lawn SD, Wilkinson RJ, 2006. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 28 : 625–633. [Google Scholar]
  3. Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, Trovati S, Parravicini C, Corbellino M, Meroni L, 2007. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br J Dermatol 157 : 1032–1036. [Google Scholar]
  4. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 : 1739–1746. [Google Scholar]
  5. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38 : 1266–1272. [Google Scholar]
  6. TDR 2007. Eighteenth Programme Report/Progress 2005–2006. Available at: www.who.int/tdr. Accessed September 27, 2007.
  7. Sindermann H, Engel KR, Fischer C, Bommer W for the Miltefosine Compassionate Use Program, 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39 : 1520–1523. [Google Scholar]
  8. Schraner C, Hasse B, Hasse U, Bauman D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Günthard HF, 2005. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40 : e120–e124. [Google Scholar]
  9. Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE, 2006. Successful treatment of post-kala-azar-dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 53 : e25–e27. [Google Scholar]
  10. Dejenie Belay A, Asafa Y, Mesure J, Davidson RN, 2006. Successful miltefosine treatment of post-kala-azar-dermal leishmaniasis occurring during antiretroviral treatment. Ann Trop Med Parasitol 100 : 223–227. [Google Scholar]
  11. Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V, 2006. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. Trans R Soc Trop Med Hyg 100 : 698–700. [Google Scholar]
  12. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, Bossi L, Germagnoli L, Lazzarin A, Uberti-Foppa C, Cinque P, 2003. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41 : 5080–5084. [Google Scholar]
  13. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33 : 57–61. [Google Scholar]
  14. Pérez-Victoria FJ, Sánchez-Cañete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F, 2006. Mechanism of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 9 : 26–39. [Google Scholar]
  15. Berman J, Bryceson ADM, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA, 2006. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 100S : S41–S44. [Google Scholar]
  16. Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100S : S17–S20. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.79.715
Loading
/content/journals/10.4269/ajtmh.2008.79.715
Loading

Data & Media loading...

  • Received : 25 Dec 2007
  • Accepted : 08 Apr 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error